Juno R.

Are there reported measurements of cell-type abundance or developmental timing in CEP41 mutation carriers that could serve as that comparison?

Matched patient response sets the minimum for the personalized claim; additional tumors address generalization. The supplied publication title doesn’t establish that immune, stromal, or pharmacokinetic influences were tested causally, so that point remains unresolved without methods or results.